Anke Biotechnology's atosiban injection approved for market

Anhui Anke Biotechnology Group (SZSE:300009) announced that it has received approval from the National Medical Products Administration for its Atosiban Acetate Injection. Classified as a Category 4 chemical drug, the injection is approved under registration numbers 国药准字 H20254203 and 国药准字 H20254204. Atosiban is a selective oxytocin receptor antagonist used to delay imminent preterm labor in pregnant women, where the injection meets specific requirements. Anke Biotechnology believes this approval will enhance the company's product structure in the field of assisted reproduction and boost market competitiveness. The company advises investors to exercise caution due to potential market and environmental uncertainties.